Clinical trial
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine…
NCT00363051 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00363051 |
|---|---|
| Title | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy |
| Official title | An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | Everolimus 10 mg, Octreotide Depot |
| Enrollment | 160 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Apr 1, 2012 |
| First posted | Aug 15, 2006 |
| Last update posted | May 10, 2013 |
| Countries | Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: